ReviewJournal of gastric cancer2026
Molecular Imaging in Gastric Cancer: [¹⁸F]FDG and Fibroblast Activation Protein-Targeted PET/CT.
Review in Journal of gastric cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Personalized PET Imaging in Gastric Cancer: An Umbrella Review of Meta-Analyses to Guide Radiopharmaceutical Selection and Clinical Indication.International journal of biomedical imaging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Gastric cancer remains a major global health burden, and accurate staging and response assessment are essential for optimal management. 2-[¹⁸F]-Fluoro-2-deoxy-D-glucose ([¹⁸F]FDG) positron emission tomography (PET)/computed tomography (CT) is widely used in oncology. However, it exhibits variable sensitivity in gastric cancer, particularly in poorly cohesive, mucinous, and signet ring cell carcinomas with low glucose metabolism. These limitations have prompted interest in fibroblast activation protein-targeted imaging, which visualizes the tumor stroma rather than the tumor cells. Radiolabeled fibroblast activation protein inhibitors (FAPIs) exhibit high tumor-to-background contrast and consistent uptake across histological subtypes, offering improved lesion detectability even in [¹⁸F]FDG-negative tumors. This review outlines the evolving role of PET/CT in gastric cancer, with a focus on [¹⁸F]FDG and FAPI tracers. Comparative evidence indicates that FAPI PET/CT enhances diagnostic accuracy, provides complementary information for evaluating treatment response, and offers potential theranostic applications. Further prospective studies are needed to establish standardized protocols and define the clinical impact of FAPI PET/CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.